Related Experiment Videos
Switching antidepressants for treatment-resistant major depression
1Department of Psychiatry, Baylor College of Medicine, Houston, Tex 77030, USA. laurenm@bcm.tmc.edu
The Journal of Clinical Psychiatry
|September 29, 2001
Summary
Switching antidepressant medications is a common strategy for major depression when initial treatments fail. This approach offers benefits like lower costs and better adherence, with response rates around 50%.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Many patients with major depression do not achieve adequate symptom relief with initial antidepressant therapy.
- Switching to a different antidepressant monotherapy is a frequently considered strategy for non-responders.
Purpose of the Study:
- To review clinical considerations and evidence for switching antidepressant medications in major depressive disorder.
- To discuss practical aspects of antidepressant switching, including timing and methodology.
Main Methods:
- Literature review of clinical considerations and available evidence on switching antidepressants.
- Summary of open-trial data regarding response rates for antidepressant monotherapy switching.
Main Results:
- Switching to a different monotherapy is a preferred option, offering advantages such as reduced costs, fewer drug interactions, and improved adherence.
- Open trials suggest response rates of approximately 50% for antidepressant switching, comparable to augmentation strategies.
Conclusions:
- Antidepressant switching is a viable strategy for patients with major depression who show insufficient response to initial treatment.
- Evidence from open trials indicates comparable efficacy between switching monotherapy and augmentation strategies, with practical benefits favoring switching.